NHS patients to receive AbbVie’s Skyrizi for plaque psoriasis following NICE recommendation

pharmafile | August 21, 2019 | News story | Research and Development, Sales and Marketing AbbVie, NICE, Skyrizi, pharma 

AbbVie’s Skyrizi (risankizumab) has been awarded a positive recommendation from UK drug watchdog NICE, meaning that the IL-23 inhibitor will now be made available to eligible patients across England and Wales for the treatment of plaque psoriasis in those who have failed conventional systemic therapies, the company has announced.

The drug, which is jointly developed along with Boehringer Ingelheim, navigated the organisation’s Fast Track pathway; the institute’s decision will now be implemented within 30 days as opposed to the traditional 90.

The ruling was based on data which showed Skyrizi demonstrated high rates of skin clearance after 16 weeks of use, which was maintained through 52 weeks of treatment.

Around 820,000 people are affected by the chronic condition plaque psoriasis in the UK.

Advertisement

The decision means that eligible patients can access the therapy almost two months earlier than via the conventional pathway.

Matt Fellows

Related Content

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

The Gateway to Local Adoption Series

Latest content